highly conserved conformational fusion-loop epitope in GP with subnanomolar affinity and enhanced targeting of a cleaved GP intermediate generated in late endosomes. In vivo , ADI-15878 fully protected mice challenged with EBOV and SUDV and partially protected ferrets challenged with BDBV 8, 9 .
Because previous work has demonstrated the predictive value of the guinea pig models of ebolavirus challenge for therapeutic antibody efficacy in nonhuman primates [10] [11] [12] , we exposed guinea pigs to a uniformly lethal dose of guinea pig-adapted EBOV (EBOV-GPA) 13 and then treated them with equivalent doses of ADI-15878 or the ZMapp cocktail 2 at 3 days post-challenge. Monotherapy with ADI-15878 afforded only 40-50% survival, and was less effective than ZMapp (70-100% survival), supporting prior observations that mAb cocktails targeting multiple GP epitopes may be necessary for complete protection ( Fig. 1A-B ) 1, 2, 8, [14] [15] [16] .
Accordingly, we sought to identify one or more suitable partner mAb(s) for ADI-15878.
Potential cocktail components were filtered on the basis of: (i) their host origin (human or nonhuman primate); (ii) neutralization potency (50% inhibition of EBOV infectivity [IC 50 ] <10 nM); (iii) anti-ebolavirus binding and neutralization breadth (recognition and neutralization of EBOV, BDBV, and SUDV); (iv) neutralization of both uncleaved and endosomally cleaved forms of ebolavirus GP, a feature previously associated with antiviral potency and breadth 8, 16 ; (v) lack of cross-reactivity with the secreted glycoprotein sGP present at high levels in EVD patients (to prevent sGP from "soaking up" circulating mAbs) 17, 18 ; and (vi) demonstrated post-exposure protection against EBOV in mice. This selection process yielded two candidates, ADI-15946 8, 9 and CA45 16 . Like ADI-15878, these broadly neutralizing mAbs recognize conserved conformational epitopes in the "base" subdomain of the trimeric GP spike ( Fig. 1C ) 8, 16 , raising the possibility that they can compete with ADI-15878 for GP binding and limit cocktail efficiency. Indeed, preincubation of EBOV GP with saturating amounts of ADI-15878 abolished binding by CA45 in a biolayer interferometry assay ( Fig. 1D ) but did not interfere with ADI-15946 binding ( Fig. 1E ), indicating that ADI-15878 and CA45 compete for GP recognition, whereas ADI-15878 and ADI-15946 do not. Therefore, we selected ADI-15946 for further evaluation as a cocktail partner for ADI-15878.
We previously showed that ADI-15946 neutralizes EBOV, BDBV, and SUDV; however, it is less potent against SUDV 8 (see Fig. 3A ). This neutralization deficit arises from the reduced binding affinity of ADI-15946 for SUDV GP relative to EBOV GP ( Figs. 2A and Extended Data Fig 2A ) , consistent with the sequence divergence between these glycoproteins at the proposed sites of mAb contact 8 . To ensure that our mAb cocktail effectively targets all known virulent ebolaviruses at two distinct sites, we sought to specificity-mature ADI-15946 to SUDV GP using yeast-display technology 19 . Libraries were generated by introducing diversity into the ADI-15946 heavy and light chains (HC and LC, respectively) through oligonucleotide-based mutagenesis and transformation into Saccharomyces cerevisiae by homologous recombination. , we assessed the polyspecificity of ADI-15946 and ADI-23774 as described 19, 21 . Fortuitously, specificity maturation also reduced ADI-23774's nonspecific binding relative to that of ADI-15946 ( Fig. 2D ) . Thus, both ADI-15878 and ADI-23774 display a low level of polyspecificity, a highly desirable property for early-stage therapeutic candidates.
Concordant with ADI-23774's improved binding to both recombinant GP proteins ( ADI-23774's increased effectiveness against SUDV did not compromise its capacity to neutralize EBOV and BDBV ( Fig. 3A, C ).
To assess the effects of these gains in neutralization potency on mAb protective efficacy, we evaluated ADI-23774 in murine models of EBOV 22 and SUDV 23 challenge. ADI-23774
resembled ADI-15946 in its capacity to protect animals from challenge with mouse-adapted EBOV when administered 3 days post-exposure ( To evaluate the protective potential of MBP134, we exposed guinea pigs to a uniformly lethal dose of EBOV-GPA and then treated them with increasing doses of MBP134 at 3 days post-challenge ( Fig. 4A-B ). Treatment with 2.5-3.3 mg of MBP134 (total mAb dose) per animal afforded near complete protection ( Fig. 4A ), whereas treatment with ADI-15878 alone at 2.5-5 mg per animal afforded ≤50% protection ( Fig. 1A ) , providing evidence for the superior efficacy of the cocktail over the monotherapy.
To further enhance the in vivo potency of MBP134, we set out to optimize an orthogonal property of its component mAbs-their capacity to harness the host antiviral innate immune response through antigen-dependent engagement of activating Fc receptors on immune cells.
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Because cytolysis by natural killer (NK) cells has been demonstrated to play a critical role in protection against EBOV infection 25 , we measured the EBOV GP-dependent activation of human NK cells derived from four seronegative human donors by ADI-15878 and ADI-23774. Both mAbs were poorly active, as judged by their limited capacity to induce three markers of NK cell activation-degranulation ( Fig. 4C ) , and production of IFN-γ ( Fig. 4D ) and MIP-1β ( Fig.   4E ) post-challenge was required to fully protect animals from EBOV-GPA ( Fig. 4F-G ) -an approximately twofold reduction in dosage relative to the parent MBP134 cocktail (P=0.0064) ( Fig. 4A ). Moreover, a single MBP134 AF dose as low as 0.8 mg administered at 4 days 7 post-challenge was sufficient to fully protect guinea pigs challenged with guinea pig-adapted SUDV (SUDV-GPA) 32 ( Fig. 4H ) . Remarkably, MBP134 AF afforded 70-100% protection from SUDV-GPA challenge (at 2.5-5.0 mg total mAb dose) even when treatment was delayed to 5 days post-challenge ( Fig. 4I ). These are, to our knowledge, the lowest single doses (0. 
